|
gptkbp:instance_of
|
gptkb:monoclonal_antibody
|
|
gptkbp:bfsLayer
|
3
|
|
gptkbp:bfsParent
|
gptkb:temple
|
|
gptkbp:activities
|
IL-5 receptor antagonist
|
|
gptkbp:appointed_by
|
subcutaneous injection
|
|
gptkbp:approves
|
gptkb:FDA
2017-11-14
|
|
gptkbp:availability
|
prescription only
|
|
gptkbp:class
|
gptkb:monoclonal_antibody
|
|
gptkbp:clinical_trial
|
gptkb:SIROCCO
Phase III
severe asthma
CALIMA
ZONDA
|
|
gptkbp:contraindication
|
hypersensitivity to benralizumab
|
|
gptkbp:developed_by
|
gptkb:temple
|
|
gptkbp:dosage_form
|
injection
|
|
gptkbp:duration
|
every 4 weeks for the first 3 doses, then every 8 weeks
|
|
gptkbp:effective_date
|
gptkb:2017
|
|
gptkbp:formulation
|
solution for injection
|
|
gptkbp:frequency
|
every 8 weeks after initial doses
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Fasenra
|
|
gptkbp:indication
|
eosinophilic asthma
|
|
gptkbp:ingredients
|
gptkb:benralizumab
C646 H1008 N174 O198 S4
|
|
gptkbp:interacts_with
|
none known
|
|
gptkbp:invention
|
gptkb:temple
|
|
gptkbp:is_monitored_by
|
eosinophil counts
|
|
gptkbp:is_used_for
|
gptkb:asthma
|
|
gptkbp:manager
|
subcutaneous
|
|
gptkbp:marketed_as
|
gptkb:legislation
gptkb:United_States
|
|
gptkbp:pharmacokinetics
|
long half-life
reduces eosinophil levels
|
|
gptkbp:population
|
adults and children 12 years and older
|
|
gptkbp:price
|
high
|
|
gptkbp:regulatory_compliance
|
approved
|
|
gptkbp:safety_features
|
generally well tolerated
|
|
gptkbp:side_effect
|
headache
back pain
injection site reactions
hypersensitivity reactions
pharyngitis
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:targets
|
gptkb:interleukin-5
eosinophils
|
|
gptkbp:traded_on
|
gptkb:Fasenra
|
|
gptkbp:type_of_care
|
important for efficacy
|
|
gptkbp:website
|
upper arm, thigh, abdomen
|